IN BRIEF: SkinBioTherapeutics loss widens as underperforms in US

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

SkinBioTherapeutics PLC- Skin health-focused life sciences company - Says pretax loss widens to £1.2 million in six months to December 31, from £628,241 a year earlier. US market penetration with its only product launched in October 2021, AxisBiotix-Ps, for treating Psoriasis, was slower than expected, company adds. Revenue for the half comes in at £21,949, against none a year earlier. For the financial year ending in June, the company expects revenue materially below expectations, it warns.

Current stock price: 37.27 pence, down 18% on Tuesday

12-month change: down 21%

Copyright 2022 Alliance News Limited. All Rights Reserved.